Liaoning Chengda Biotechnology Co. Ltd. Class ASSE: 688739

"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on the Initiation of Phase I Clinical Trial for Influenza Vaccine (Split Virion, High-Dose)

Jul 18, 2026 · Issued by Liaoning Chengda Biotechnology Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on the Initiation of Phase I Clinical Trial for Influenza Vaccine (Split Virion, High-Dose)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Liaoning Chengda Biotechnology Co. Ltd. Class A

"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual ReportJul 11
"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on the Influenza Virus Split Vaccine Obtaining Drug Registration Certificate and Passing GMP Compliance InspectionJul 3
Announcement on Obtaining Drug Registration Certificate for Quadrivalent Influenza Vaccine (Split Virion) and Passing GMP Compliance Inspection for DrugsJun 17
Announcement on Implementation Result of Shares Repurchase and Share ChangesJun 12

All Liaoning Chengda Biotechnology Co. Ltd. Class A news releases